Long Acting ARVs

Long acting parenteral (LAP) antiretrovirals (ARVs) are in development for both the treatment and prevention of HIV. It is estimated that the first LAP ARV could be available (most likely as PrEP) within five years. It is reported that combination ARVs that can be used as complete treatment regimens will take significantly longer to complete research and development and to be made available for use.